Clinical Trials in Chicago

Showing 12721-12740 of 17,609 trials

DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma

NCT02815397

Newly diagnosed histologically confirmed c-myc+ de novo DLBCL. Metformin 500 mg daily x 1 week, then 500 mg twice daily (BID) x 2 weeks, then 850 mg twice daily until 1 month after last cycle of chemo-immunotherapy. DA-EPOCH-R every 21 days x 4 cycles (CNS prophylaxis single or triple therapy given intrathecally each cycle to patients deemed appropriate by treating physician). Restage after 4 cycles with CT. Complete remission or partial remission: complete 2 more cycles or radiation therapy (XRT) consolidation per physician. Stable or progressive disease will go on to salvage therapy off study.

Diffuse Large B-Cell Lymphoma

Rush University Medical Center2 participantsStarted Feb 2016

Chicago, Illinois, United States

COMPLETEDPhase 32.2 miles

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

NCT01632904

The purpose of the RELIEF study is to compare symptoms in polycythemia vera (PV) subjects treated with ruxolitinib versus subjects treated with hydroxyurea (HU) as measured by the percent of subjects who achieve a clinically meaningful symptom improvement (ie, total symptom score reduction of ≥ 50% reduction) at Week 16 compared to Baseline. The study is also designed to demonstrate that these responses are durable with continued treatment.

Polycythemia Vera

Incyte Corporation110 participantsStarted Jun 2012

Scottsdale, Arizona, United States • Fayetteville, Arkansas, United States • Burbank, California, United States +67 more locations

DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Find Trials by Condition in Chicago

TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)

A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis

Extended Follow-Up After Islet Transplantation in T1D

Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-612)

Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body Weight

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Proof of Concept (POC) in Patients With Ischaemic Stroke

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

Evaluating the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Adults and Adolescents

An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

VEG111485: A QTc Study of Pazopanib

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Natural Evolution of AV Conduction Disorders in Patients Implanted With Cardiac Pacemakers

Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (F.A.M.E.)